Post hoc analyses of SURMOUNT-OSA trial data suggest that the combined effects of weight loss and better obstructive sleep apnoea control using tirzepatide improve cardiometabolic risk factors more than weight loss alone. The findings underscore how sleep health and metabolic health are interconnected.
Follow-up analyses of data from the SURMOUNT-OSA trial indicate that tirzepatide may reduce cardiometabolic risk by treating both obstructive sleep apnoea (OSA) and obesity. The researchers evaluated the impact of weight loss alone, reduction in OSA severity alone and the combination of the two.
OSA is a common disorder in which breathing repeatedly stops and starts during sleep because throat muscles relax and block the upper airway. As well as resulting in daytime tiredness and problems with concentration, OSA can have major cardiometabolic consequences. It associated with obesity, and weight reduction can notably improve OSA severity.
Continuous positive airway pressure (CPAP) has been first-line therapy for OSA but is often poorly tolerated. As weight reduction yields notable OSA improvements in those who are obese, interest in tirzepatide as a treatment has grown owing to its effects on weight loss.
The SURMOUNT-OSA programme demonstrated that tirzepatide was superior to placebo in reducing OSA severity, both in CPAP users and non-users. Among participants with moderate-to-severe OSA and obesity, tirzepatide significantly reduced various cardiometabolic risk factors, including inflammation, prediabetes and triglycerides.
The secondary analyses sought to understand the drivers of these improvements by analysing the impact of weight loss alone, of changes in OSA severity alone and the combination of the two. While weight loss alone had marked effects, the benefits of combined weight loss and improvements in OSA were superior.
The findings support the idea that treating OSA and obesity in individuals with both conditions is required to optimise cardiometabolic benefits. In clinical practice, the treatment of OSA in people with obesity should include obesity management, with weight-loss therapies such as tirzepatide representing a potential option.
The full study, published in Nature Medicine, can be read here.
Journal of
Diabetes Nursing
Issue:
Early View
Holistic treatment of OSA and obesity key to optimising cardiometabolic benefits of tirzepatide
Follow-up analyses of data from the SURMOUNT-OSA trial indicate that tirzepatide may reduce cardiometabolic risk by treating both obstructive sleep apnoea (OSA) and obesity. The researchers evaluated the impact of weight loss alone, reduction in OSA severity alone and the combination of the two.
OSA is a common disorder in which breathing repeatedly stops and starts during sleep because throat muscles relax and block the upper airway. As well as resulting in daytime tiredness and problems with concentration, OSA can have major cardiometabolic consequences. It associated with obesity, and weight reduction can notably improve OSA severity.
Continuous positive airway pressure (CPAP) has been first-line therapy for OSA but is often poorly tolerated. As weight reduction yields notable OSA improvements in those who are obese, interest in tirzepatide as a treatment has grown owing to its effects on weight loss.
The SURMOUNT-OSA programme demonstrated that tirzepatide was superior to placebo in reducing OSA severity, both in CPAP users and non-users. Among participants with moderate-to-severe OSA and obesity, tirzepatide significantly reduced various cardiometabolic risk factors, including inflammation, prediabetes and triglycerides.
The secondary analyses sought to understand the drivers of these improvements by analysing the impact of weight loss alone, of changes in OSA severity alone and the combination of the two. While weight loss alone had marked effects, the benefits of combined weight loss and improvements in OSA were superior.
The findings support the idea that treating OSA and obesity in individuals with both conditions is required to optimise cardiometabolic benefits. In clinical practice, the treatment of OSA in people with obesity should include obesity management, with weight-loss therapies such as tirzepatide representing a potential option.
The full study, published in Nature Medicine, can be read here.
What’s hot in diabetes nursing? April 2026
Report highlights unmet needs in diabetes care for autistic people
Editorial: Reflection, not rumination: why headspace matters in nursing practice
Simple screening test may help detect undiagnosed heart failure in diabetes
Editorial: NICE NG28 update: tailoring type 2 diabetes management and cardiorenal health
Changing the course of type 1 diabetes: screening and early immunotherapy
European type 1 diabetes screening initiative reaches key milestone
Put the kettle on and see what's stirring in the diabetes world.
20 Apr 2026
Interviews provide new insights into challenges autistic people face.
20 Apr 2026
In her editorial, Julie Brake discusses how protected headspace can turn chaos into solutions.
17 Apr 2026
Heart-failure screening programme could reduce hospitalisation and death.
7 Apr 2026